ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms

Riabov, V., Xu, Q., Schmitt, N., Streuer, A., Ge, G., Bolanos, L., Wunderlich, M., Jann, J.-C., Wein, A., Altrock, E., Demmerle, M., Mukherjee, S., Ali, A. M., Rapp, F., Nowak, V., Weimer, N., Obländer, J., Palme, I., Göl, M., … Nowak, D. (2023). <i>ASXL1</i> mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms. Haematologica, 0–0. https://doi.org/10.3324/haematol.2023.282921
Authors:
Vladimir Riabov
Qingyu Xu
Nanni Schmitt
Alexander Streuer
Guo Ge
Lyndsey Bolanos
Mark Wunderlich
Johann-Christoph Jann
Alina Wein
Eva Altrock
Marie Demmerle
Sanjay Mukherjee
Abdullah Mahmood Ali
Felicitas Rapp
Verena Nowak
Nadine Weimer
Julia Obländer
Iris Palme
Melda Göl
Ahmed Jawhar
Ali Darwich
Patrick Wuchter
Christel Weiss
Azra Raza
Jason M Foulks
Daniel T Starczynowski
Feng-Chun Yang
Georgia Metzgeroth
Laurenz Steiner
Mohamad Jawhar
Wolf-Karsten Hofmann
Daniel Nowak
Affiliated Authors:
Sanjay Mukherjee
Abdullah Mahmood Ali
Azra Raza
Columbia Affiliation:
Subjects:
Azacitidine (MeSH)
Myelodysplastic Syndromes (MeSH)
Mutation (MeSH)
Piperidines (MeSH)
Repressor Proteins (MeSH)
Flavonoids (MeSH)
elink
Publication Type:
Article
Unique ID:
10.3324/haematol.2023.282921
PMID:
37916386
DOI:
10.3324/haematol.2023.282921
Journal:
Haematologica
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: